Method of treatment of endometritis in animals
FIELD: veterinary medicine.
SUBSTANCE: method comprises the use of chemotherapeutic agents. The chemotherapeutic agent is used as N,N-dimethylamino-propylamides of fatty acids of the formula 1 which are used in the form of salts with pharmacologically acceptable acids.
EFFECT: use of the claimed invention is highly effective for treatment of endometritis in animals.
4 tbl, 2 ex
The invention relates to the field of agriculture and veterinary medicine, and in particular to methods of treatment of endometritis in animals.
There is a method of treatment of endometritis in animals with the use of probiotic agents (E. Novikova N. Thesis for the candidate of veterinary Sciences. Krasnodar, 2013).
There is a method of treatment of endometritis in animals with antibiotics and sulfonamides (Worms D. K. and other Drugs in veterinary medicine. Handbook, 1977, S. 296, 302, 304, 307, 328, 329, 331), chosen as a prototype.
There is a method of treatment of endometritis in animals using furazolidone sticks. The disadvantage of this method is the impossibility of introducing sticks with a sharp narrowing of the cervical canal (the Handbook. Veterinary medicines. Edited by A. D. Tretyakov. M: Agropromizdat, 1988, S. 30-31).
The use of antibiotics, nitrofuranov and sulfonamides for the treatment of endometritis is becoming less effective due to the emergence of resistant strains of microorganisms. In addition, in the treatment of endometritis in cows is the contamination of milk antibacterial drugs, which in turn exacerbates the situation with the ineffectiveness of the antibiotic therapy not only in veterinary medicine, but also in medicine.
The aim of the invention is to develop a new effective way for the treatment of endometritis in animals.
This objective is achieved in that, as an active substance in the developed method for the treatment of endometritis in animals used amides of acids of formula 1(n=14; 16), which are used in the form of salts with pharmacologically acceptable acids (hydrochloric, sulfuric, phosphoric, maleic, succinic and other):
The chemical name of compound 1(n=14): palmitic acid (3-dimethylamino-propyl) amide.
The chemical name of compound 1(n=16): stearic acid (3-dimethylamino-propyl) amide.
Amides of 1 is obtained from the corresponding acids 2(n=14; 16), according to the scheme:
Example obtain the amide of palmitic acid 1(n=14):
The mixture 25.64 g (0.1 mol) of palmitic acid 2(n=14) and 10.21 g (0.1 mol) of the amine 3 is heated at 150-155°C for 4 hours with distillation of the volatile products, then at 170-175°C for 30 minutes with distillation of the volatile products. Cooled and the resulting product 1(n=14) clear column chromatography on aluminium oxide in chloroform. Output 33.37 g (98%), so pl. 59-61°C.
An NMR spectrum1N, CDCl3(δ, M. D.): 0.854-0.898 (3H, triplet); 1.248-1.273 (24N, multiplet); 1.567-1.681 (4H, multiplet); 2.112-2.163 (2H, triplet); 2.225 (6N, singlet); 2.346-2.388 (2H, triplet); 3.304-3.363 (2H, Quartet); 6.927 (1H, singlet). Found, %: C 74.40; H 12.70; N, 8.05. Calculated, %: C 74.05; H 13.02; N, 8.22.
Example obtain the amide is takenaway acid 1(n=16):
Synthesized similarly amide of palmitic acid from 28.44 g (0.1 mol) of stearic acid 2(n=16) and 10.21 g (0.1 mol) of the amine 3. Output 35.01 g (95%), so pl. 63-64°C. an NMR Spectrum1N, CDCl3(δ, M. D.): 0.854-0.898 (3H, triplet); 1.186-1.249 (28N, multiplet); 1.568-1.712 (4H, multiplet); 2.113-2.164 (2H, triplet); 2.225 (6N, singlet); 2.346-2.388 (2H, triplet); 3.304-3.363 (2H, Quartet); 6.928 (1H, singlet). Found, %: C 74.60; N, 13.20; N, 7.63. Calculated, %: C 74.93; N, 13.12; N, 7.59.
The obtained acid amides 1(n=14; 16) are used as antibacterial and protesting tools in the treatment of endometritis in animals.
Example 1. Antibacterial and Protistology activity (3-dimethylamino-propyl) amide of palmitic acid (n=14) and (3-dimethylamino-propyl) amide of stearic acid (n=16) (see table 1):
|№ p/p||The connection number||Minimum inhibitory concentration, μg/ml|
|St. aureus||E. coli||Colpoda steinii|
|1||Palmitic acid (3-dimethylamino-propyl) amide (n=14)||6,25||5,8|
|2||Stearic acid (3-dimethylamino-propyl) amide (n=16)||3,125||6,25||7,8|
Example 2. The treatment of endometritis in animals
With this purpose, prepare aqueous solutions of amides. For dissolution of amides in water, you must add the calculated amount (one equivalent) of the pharmacologically acceptable mineral or organic acids (hydrochloric, sulfuric, phosphoric, succinic, citric and other), which play a minor role, i.e. promote dissolution of amides in water, but do not have a therapeutic effect.
Using 0.1% solutions of amides 1(n=14; 16) in terms of free base. To prepare 10 liters of working solution of 0.1% concentration (in terms of free base) weigh 10 g of the corresponding amide 1(n=14; 16), mixed with 500 ml of water, add one equivalent of acid, stirred at 40-50°C until the formation of the solution and the volume was adjusted to 10 liters. In tables 2 and 3 show the amount of acid to amide 1(n=14; 16).
|The amount of acid required to prepare 10 liters of a 0.1% solution of palmitic derivative 1(n=14)|
|1.42 g in terms HCl||of 2.26 g||1,91 g||3,15 g in terms of HBr||of 4.38 g|
|The amount of acid required to prepare 10 liters of a 0.1% solution of stearic derivative 1(n=16)|
|1.28 g in terms HCl||2,03 g||1,72 g||2,84 g in terms of HBr||3.94 g|
Cows experimental groups were injected into the uterus of a 0.1% aqueous shall actor amide of palmitic and stearic acid amide in the form of salts with mineral and organic acids in a volume of 100 ml using a probe with a syringe Janet. Cows in the control group as an antibacterial agent was injected into the uterus of furazolidone sticks.
To enhance contractility of the uterus and removal of the pathological exudate from the uterine cavity sick cows all groups was applied intramuscularly 1% solution of sinistral with the subsequent introduction of oxytocin.
Fit was judged by the General condition of the animals, normalization of body temperature, lack of vaginal secretions, on hematological parameters. Comparative efficacy was assessed by the percentage of recovered animals. The test results presented in table 4.
|The test results clinical effectiveness salts of fatty acid amides 1(n=14; 16) in the form of a 0.1% aqueous solutions|
|No. of groups of animals||Medication||The number of animals in the group at the 1-day treatment||The number of sick animals in the group at the 7th laziness treatment||The percentage of recovery in the group %|
|1||Amide and palmitic acid 1(n=14) in the form of a salt with hydrochloric acid.||17||2||88,2|
|Amide and palmitic acid 1(n=14) in the form of a salt with sulfuric acid||12||2||83,3|
|3||Amide and palmitic acid 1(n=14) in the form of a salt of sorbic acid||17||1||94,1|
|4||Amide stearic acid 1(n=16) in the form of a salt with hydrochloric acid||12||0||100,0|
|5||The control group||34||14||58,8|
From table 4 it is seen that the effectiveness of the treatment of animals in the experimental group using a 0.1% solution of palmitic acid in the form of salts with hydrochloric, sulfuric and sorbic acids on the seventh day of treatment is 83,3-94,1%. Application of 0.1% solution of amide stearic acid, a salt with hydrochloric acid provided the recovery of all cows in the group on the seventh day of treatment. Thus, therapeutic effectiveness of the proposed method znachitelnaya the effectiveness of the treatment of animals in the control group (58%).
According to the study therapeutic effectiveness can also be concluded that the type of the used acid does not affect therapeutic effect.
Acute toxicity of substances.
It is established that the introduction into the stomach of laboratory rats 5% aqueous solution of 3 ml once palmitic acid amide 1(n=14), stearic acid amide 1(n=16) does not cause death in laboratory rats. Signs of acute toxic reactions in rats is not established within 10 days of the observation.
The technical result that can be achieved with the implementation of the present invention:
1. Expanding range of chemotherapeutic agents used to treat animals with endometritis.
2. Improving the efficiency of the treatment of animals with postpartum endometritis.
3. Reduced recovery time animals.
1. Veterinary medicines. The Handbook. Edited by A. D. Tretyakov. - M.: Agropromizdat, 1988, S. 207-223.
2. Veterinary medicines. The Handbook. Ed. by D. F., Osize. M.: Kolos, 1981, S. 410-414.
3. Brains I. E. Antibiotics in veterinary medicine. - M.: Kolos, 1971, S. 75-83.
The treatment of animals in endometritis, including the use of chemotherapeutic agents, characterized in that as a chemotherapeutic drug used N,N-dimethylamino-Propylamine fatty acids of formula 1(n=14; 16):
which is used in the form of salts with pharmacologically acceptable acids.
SUBSTANCE: group of inventions refers to medicine and medical equipment, namely to obstetrics and gynaecology, and can be used for the local treatment of inflammatory diseases of the uterine cavity. The method is implemented by inserting a waveguide of a presented device in a protection enclosure into the uterine cavity. A taper base of a narrow portion of the enclosure leans on an external orifice of the cervical uterus to prevent accidental perforation of the uterus. An infusion system regulator is used to set the spray supply of a therapeutic solution into an irrigation canal of the ultrasonic device. Thereafter ultrasonic vibrations are generated, and the uterine cavity is treated with the sounded therapeutic solution. The exposure length is 3-5 minutes at the ultrasonic vibration frequency of 25 kHz, infusion rate approximately 100-150 ml/min. The total infusion volume is not less than 300 ml. The ultrasonic treatment enables providing the continuous outflow of the uterine discharge. The device comprises an US generator, an acoustic assembly, the waveguide with the protection enclosure, the infusion system for the therapeutic solution supply. The acoustic assembly and waveguide comprises the irrigation canal. A working tip of the waveguide represents a short cylinder having a diameter greater than the rest portion. The irrigation canal of the waveguide has a diameter of 2 mm. The protection metal thin-wall enclosure has a crimped distal end and drain holes and represents two cylindrical elements of various diameters connected by a taper junction with milled grooves arranged so that to enable the fluid access to the working tip cylinder, the length of which makes no more than 3 mm.
EFFECT: inventions provide the effective cleansing of the uterine cavity from infected and necrotised tissues with improved comfort and safety of the procedure with using no endoscopic equipment, cervical dilation manipulations and uterine pre-probing.
2 cl, 3 dwg, 3 ex
SUBSTANCE: invention refers to veterinary science, particularly to an agent for treating and preventing endometritis in animals. The substance of the invention consists as follows. Novocaine 0.5 g is dissolved in distilled water 1 l, and the following preparations are dissolved in a solution of Novocaine 250 mg: powdered metronidazole 4.0 g is dissolved in Novocaine 250 ml; powdered ciprofloxacin 2.0 g is dissolved in Novocaine 250 ml; powdered Doxycycline 1.0 g is dissolved in Novocaine 250 ml; powdered tavegil 2.5 g is dissolved in Novocaine 250 ml; all the ingredients are combined to prepare the agent in an amount of 1 litre for treating and preventing endometritis in animals.
EFFECT: invention provides the pronounced anti-inflammatory and antimicrobial effect of a broad spectrum of action combined with reducing the body response to histamine, relieving smooth muscle spasm and reducing capillary penetration.
5 tbl, 6 ex
SUBSTANCE: invention relates to field of veterinary and is intended for treatment and prevention of postpartum acute mastitis in cows. Medication contains antimicrobial, anti-inflammatory preparations and distilled water. Medication additionally contains licorice root. As antimicrobial preparation it contains metronidazole. as anti-inflammatory preparation it contains ciprofloxacin, with the following component ratio, g/l: licorice root 80-85 g; metronidazole 3.5-4.0 g; ciprofloxacin 2.0-2.5 g; distilled water - the remaining part.
EFFECT: application of claimed medication provides expressed antimicrobial and anti-inflammatory effect with simultaneous reduction of organism's response to histamine, release of spasm of smooth muscles and reduction of permeability of capillaries.
4 tbl, 10 ex
SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and can be used for treating and managing the pregnant women suffering drug-induced hepatitis. Establishing a diagnosis of drug-induced hepatitis requires oral administration of the herbal hepatoprotectors Carsil, or Hepabene, or the vitamin-free essential phospholipids Eslidin per os or Essentiale forte N intravenously, per os in standard doses with a cessation of any other drug-induced therapy, in the 1st trimester of pregnancy in case of observing a symptom-free increase of transaminase activity within 3 normal values and no counter-indications. In the 2nd trimester, a serum transaminase level up to 5 normal values requires prescribing ademetionine 400 mg intravenously N 7-10, then per os 1,600 mg/day. The therapeutic course makes 1 month. Ademetionine 800 mg intravenously N 10 + ursodeoxycholic acid 12 mg/kg/day are prescribed if observing the daily serum transaminase level of 5 to 10 normal values. Prescribing ademetionine 800 mg/day intravenously + ursodeoxycholic acid 12 mg/kg/day + prednisolone 90 mg/day is used for the daily serum transaminase level of more than 10 normal values. In the 3rd trimester, the daily serum transaminase level of below 5 normal values requires administering ademetionine 800 mg/day intravenously N10 + ursodeoxycholic acid 13 mg/kg/day. The transaminase level of 5 to 10 normal values requires prescribing ademetionine 800 mg/day intravenously + ursodeoxycholic acid 13 mg/kg/day + prednisolone 90 mg/day intravenously. A progressive increase of the daily transaminase level of above 10 normal values with underlying therapy with ademetionine 800 mg/day intravenously, ursodeoxycholic acid 13 mg/kg/day, prednisolone 120 mg/day intravenously with 3 days expected, a decrease of the daily transaminase level or a stabilization thereof are accompanied by continuing the therapy with the progression follow-up, including hepatic cytolysis values - an increase of the hepatic cytolysis values; an increase thereof is accompanied by prescribing the adequate therapy. The postpartum therapy is continued completely until liver function tests are normalised.
EFFECT: method enables preventing the pregnancy complications ensured by the timely diagnosis of drug-induced hepatitis in the pregnant women, the adequate drug-induced therapy differentiated by gestational age and a degree of manifestation of hepatic cytolysis and aiming at reducing a hepatic pathological process.
SUBSTANCE: group of inventions relates to field of veterinary. Claimed method includes obtaining antiplacental blood (APB) from young healthy horse 14 days after subcutaneous double introduction of placentolysate of cows, which contains parts of cotyledons and caruncles, with 14-day interval in dose 20 ml, and method of treatment and prevention of afterbirth retention, uterus subinvolution and postnatal endometritis in cows by application of antiplacental blood (APB), stimulating postnatal involution of genitals of newly calved cows, which is introduced subcutaneously in the area of neck two times in dose 10 ml, with 6 day interval.
EFFECT: application of antiplacental blood (APB) reduces duration of postnatal involution of genitals, which makes it possible to prevent and reduce terms of treatment of ill cows in case of afterbirth retention, uterus subinvolution and postnatal endometritis.
SUBSTANCE: invention relates to field of veterinary medicine and is intended for treatment of mastitis in sheep. method includes introduction of medication, containing antibiotic and chemical therapeutic substance, at the background of subcutaneous introduction of oxytocin in dose 10 U two times with 12-hour interval and above-udder novocaine blockade in accordance with D.D.Logvinov, by double introduction of 0.25% novocaine solution in dose 0.5 ml per 1 kg of body weight, with 48-hour interval. Used is preparation, which contains antibiotic norfloxacin as antimicrobial preparation, and dioxydin as chemical therapeutic substance, and additionally 1,2-propyleneflycol, polyvinylpyrrolidone low-molecular, disodium salt of tetraacetic acid ethylenediamine (trilon B), hydrochloric acid (0.1 mol/l) to pH 4.5, water for injections with the following component ratio, wt %: dioxydin - 1.0; norfloxacin - 5.0; 1,2-propyleneflycol - 19.8; polyvinylpyrrolidone low-molecular - 0.2; disodium salt of tetraacetic acid ethylenediamine (trilon B) - 0.01; hydrochloric acid (0.1 mol/l) to pH 4.5-5.5; water for injections - to 100.0. Preparation is introduced intramuscularly in dose o.1 ml/kg of body weight two times per day until clinical recovery, for all forms of mastitis.
EFFECT: claimed invention makes it possible to provide expressed therapeutic effect.
2 tbl, 2 ex
SUBSTANCE: invention refers to veterinary science and aims at treating subclinical mastitis in cows. The method involves intracisternal administration of an activated physiologic saline. The activated physiologic saline is administered in the concentration of 600 mg/l in a dose of 20 ml after afternoon milking three days running. Additionally Trivyt 10 ml is intramuscularly injected on the first therapeutic day.
EFFECT: using the declared invention enables more effective treatment and reduced period of recovery.
2 tbl, 3 ex
FIELD: veterinary medicine.
SUBSTANCE: therapeutic agent is used as N,N-dimethylamino-prolinamide of oleic acid of the formula 1 , which is used as the aqueous solutions of its salts with pharmacologically acceptable acids.
EFFECT: high therapeutic effect in treatment of endometritis of animals.
2 tbl, 1 ex
SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and concerns a platform for the delivery of a silver ion releasing compound for treating menorrhagia. The platform comprises a physiologically inert flexible flat spiral sized up to be introduced into a female's uterine cavity, as well as comprises a tissue-necrotising amount of a solid, water-soluble silver salt. The silver ions are delivered to an endometrium to cause the endometrial tissue necrosis. The silver ions stayed inside the uterine cavity can be neutralised by sodium chloride solution delivered to the uterus, e.g. by a catheter, and the carrier can be removed from the uterus.
EFFECT: invention provides extending the range of products, as well as presents the improved agent for treating by more accurate silver nitrate delivery into the uterine cavity.
22 cl, 1 ex, 2 dwg
SUBSTANCE: invention refers to medicine, namely to obstetrics and gynaecology, and can be used for treating anaemia in pregnant women. That is ensured by determining the blood serum iron concentration. If the serum iron concentration is less than 13.0 mcmole/l, chronoferrotherapy combined with hyperbaric oxygenation (HBO) is prescribed. The chronoferrotherapy is conducted for 30-50 days with the use of the Sorbifer Durules preparation taken daily in a single dose in the evening from 8 pm to 10 pm., while the hyperbaric oxygenation is conducted within 5 sessions in the mode of 1.3-1.4 ata pure medical oxygen for 40 minutes.
EFFECT: method provides the higher clinical effectiveness by potentiating the therapeutic effect as a result of the combined action of the HBO and the anti-anaemic preparation; the method is easily reproducible and requires no material costs.
2 tbl, 2 ex
SUBSTANCE: invention refers to medicine, specifically to pharmaceutical compositions possessing prolonged antiarrhythmic actions and applicable to correct the cardiac arrhythmia, including that of the ischemic origin. What is presented is a pharmaceutical composition with the prolonged antiarrhythmic acitivity containing bis[2-(diethylamino)]-N-(2,6-dimethylphenyl)acetamide L-glutaminate, L-glutamic acid, 2-aminoethane sulpho-acid and excipients.
EFFECT: prolonged antiarrhythmic action and stability of the dosage form (tablets, capsules for oral application or solution for injections).
3 cl, 4 tbl
SUBSTANCE: invention relates to novel hexasubstituted para-aminophenols: where R=C6H5, C6H4Cl, C6H4Br, C6H4CH3, with arylamide groups in 2,6 positions with respect to hydroxyl, which demonstrate antibacterial activity.
EFFECT: hexasubstituted para-aminophenols with arylamide groups in 2,6 positions with respect to hydroxyl, possessing high bactericidal and bacteriostatic activity.
1 tbl, 4 ex
SUBSTANCE: invention refers to medicine, particularly to methods of treating cystitis of various origins. Increasing the clinical effectiveness and reducing a probability of recurrences are ensured by administering therapeutically active and gel preparations possessing a high adhesion to urothelium walls. The method involves instilling sodium alginate in the form of Colegel gel containing the therapeutically active preparations dioxidine, lidocaine, deoxyribonucleate, sodium hyaluronate in a therapeutically effective amount with the instillation procedure suggested to be performed according to the schedule specified depending on the cystitis origin. If observing chronic bacterial recurrent cystitis, the following schedule is presented: instillations of Colegel-ADL from the 1st to 10th therapeutic day daily, instillations of Colegel-DNK-L from the 11th to 20th therapeutic day every second day, 2-month instillation of Colegel-Hyal once a week. Treating radiation and interstitial cystitis requires the following therapeutic schedule: instillations of Colegel-ADL from the 1st to 20th day, while Colegel-DNK-L and Colegel-Hyal are instilled once twice a week from the 21st to 56th day alternated every second day. The presented therapeutic schedules using the given therapeutically active preparations enabling relieving pain, reducing a rate and a length of recurrent cystitis.
EFFECT: using these therapeutic schedules is high-efficient and safe.
SUBSTANCE: invention refers to medicine, namely to thoracic surgery, and can be used to close defects of the lower one-third of the oesophagus. A laparotomy and a sagittal diaphragmotomy are performed. The oesophageal wall defect is closed with a single-layer uninterrupted absorbable mass suture. The suture is started from the proximal end of the defect with the first knot tightened into the oesophageal lumen. A fundoplication cuff is created with covering the suture with the stomach. One of the gastric walls is fixed by interrupted sutures surrounding the closed oesophageal defect to form a cavity between the closed oesophageal defect and the gastric wall. The cavity is filled with Coletex ADL hydrogel tissue. The fundoplication cuff is fixed by interrupted sutures circularly to the diaphragm. The pleural spaces, mediastinal and subphrenic space are drained.
EFFECT: method provides reducing the time of recovery, reducing a probability of postoperative complications and faster rehabilitation by forming the reliable sutures, long bactericidal effect on the suture area, dividing the pleural space and abdominal cavity.
SUBSTANCE: invention relates to a set, containing calcium sulphate hemihydrates, pressed particles of calcium sulphate dehydrate, additionally containing one or more therapeutically, preventively and/or diagnostically active substances, and sodium-carboxymethylcellulose (Na-CMC) and a water medium, including water. The ratio R of sodium-carboxymethylcellulose and calcium sulphate in the set constitutes from 0.1 mg of sodium-carboxymethylcellulose (calculated as Na-CMC)/g of calcium sulphate to 8 mg of sodium-carboxymethylcellulose (calculated as Na-CMC)/g of calcium sulphate. When mixed, the said components of the set form a bioresorbable ceramic composition. The invention also relates to the application of the set for the treatment of a disease or condition, associated with prostate. Also claimed is a composition ready for application in the form of a paste for introduction to a patient during the time period from 5 minutes to 1 hour before hardening, obtained by mixing the components of the set. Also claimed are: a hardened composition and a method of obtaining the hardened composition or the composition ready for application.
EFFECT: control of the time of the set and composition hardening.
13 cl, 12 tbl, 9 ex
SUBSTANCE: patient is laid on his/her side opposite a block region. A guide mark is a vertical line in a projection of Petit's triangle from the twelfth rib to a wing of ilium. A needle is pricked into the skin on the vertical line at 1.5-2.5cm above the wing of ilium. 0.25% Novocaine is administered in layers into the skin and subcutaneous fat. The needle is advanced into the lumbar region from back to front in the medial direction along the lateral edge of broadest muscle of back at 6-8cm. Novocaine 120ml is administered into the lower order of the lumboiliac fossa formed in this region.
EFFECT: effective and safe pain management in the given category of patients by providing the required Novocaine concentration in the retroperitoneal space.
1 dwg, 1 ex
SUBSTANCE: invention relates to new amine derivatives of the following structural formula:
which have properties of an inhibitor of isomerase activity of a retinoid cycle. In formula (A) Z represents -C(R9)(R10)-C(R1)(R2)- or -X-C(R31)(R32); X represents -O-, -S-, -S(=O)-, -S(=O)2- or -N(R30)-; G is chosen from -C(R41)2-C(R41)2-R40, -C(R42)2-S-R40, -C(R42)2-SO-R40, -C(R42)2-SO2-R40 or -C(R42)2-O-R40; R40 is chosen from -C(R16)(R17)(R18), C6-10aryl; each R6, R19, R34, R42 has been independently chosen from hydrogen or C1-C5alkyl; each R1 and R2 has been chosen independently from each other from hydrogen, halogen, C1-C5alkyl or -OR6; or R1 and R2 together form oxo; each R3, R4, R30, R31, R32, R41 represents hydrogen; each R9 and R10 has been chosen independently from each other from hydrogen, halogen, C1-C5alkyl or -OR19; or R9 and R10 form oxo; or possibly R9 and R1 together form a direct link to provide a double link; or possibly R9 and R1 together form a direct link and R10 and R2 together form a direct link to provide a triple link; n is equal to 0 or 1; values of radicals R11, R12, R16-R18, R23, R33 are given in the formula of the invention. The invention also relates to a pharmaceutical composition containing the above compounds, to application of compounds for production of a medicinal agent for treatment of a retinal ophthalmological disease, reduction of a lipofuscin pigment accumulated in an eye, for inhibition of dark adaptation of rod photoreceptor cell of retina, inhibition of regeneration of rhodopsin in the rod photoreceptor cell of retina or inhibition of degeneration of a retinal cell in retina.
EFFECT: improved properties of derivatives.
18 cl, 2 dwg, 17 tbl, 195 ex
FIELD: veterinary medicine.
SUBSTANCE: active compound is used as amides 1 of palmic acid (n=14), amides 1 of stearic acid (n=16) and amides of oleic acid in the form of salts with mineral or organic acids.
EFFECT: method is highly effective in treatment of coccidiosis of birds.
5 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: claim describes a standard solid dosage form for oral administration which represents a mini-tablet having a core and an outer coating, wherein the core contains a therapeutically effective amount of aliskiren or its pharmaceutically acceptable salt, while the outer coating represents a film coating containing a taste masking material specified in polyacrylates, and/or a release modifying ingredient of the coating specified in cellulose derivatives and acryl copolymers, and a mixture thereof. The above mini-tablet has a size of 1 mm to 4 mm and contains aliskiren in an amount making 2 mg/tablet to 4 mg/tablet. The oral solid dosage form is preferentially applied in paediatrics.
EFFECT: according to the invention, the dosage form of aliskiren can be dosed and possesses a taste that makes it applicable for children, and maintains a biological availability at a level comparable to that of the available medicinal product for adults.
19 cl, 13 dwg, 5 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to medicine, namely to pharmacology, and deals with a synthetic biologically active compound - hydrochloride of 2-(diethylamino)ethyl ether of 9-hydroxy-9H-fluorene carboxylic acid, representing an amyzilum M-cholinoblocker derivative. The said amyzilum derivative has not been described before. The claimed compound possesses low toxicity, its synthesis is simple and available. It is demonstrated that hydrochloride of 2-(diethylamino)ethyl ether of 9-hydroxy-9H-fluorene carboxylic acid, representing the amyzilum M-cholinoblocker derivative demonstrates an expressed antidepressant activity and an anxiolytic action, possesses a sedative, and in high doses a soporific effect, it also positively influences an exploratory ability and memory. In addition, it has been stated that the claimed pharmacological substance in expressiveness of the antidepressant properties surpasses the widely applied tricyclic antidepressant amitriptylinum. The obtained data make it possible to recommend the claimed amyzilum derivative as the antidepressant for the treatment of depression and anxiety disorders.
EFFECT: invention extends an arsenal of pharmacological means, used as depression therapy.
FIELD: organic chemistry, medicine, chemical-pharmaceutical industry, pharmacology, pharmacy.
SUBSTANCE: invention relates to a medicinal agent used for prophylaxis and treatment of diseases and disorders associated with dysfunction of benzodiazepine receptors. This medicinal agent comprises compound of the formula (I)
. Compound of the formula (I) elicits high cardioprotective, neurotrophic, renoprotective activity and enhanced bioavailability.
EFFECT: valuable medicinal properties of compounds.
5 cl, 1 tbl, 1 ex